Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bisantrene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 9/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.97 |
| ▸ | NQO1 | P15559 | 1/20 | 0.97 |
| ▸ | DRD1 | P21728 | 1/20 | 0.97 |
| ▸ | ACHE | P22303 | 1/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.97 |
| ▸ | DRD3 | P35462 | 1/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.97 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.97 |
| ▸ | HTR6 | P50406 | 1/20 | 0.61 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.55 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisantrene SCHEMBL2852448 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL17819003 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL4773 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL29665174 | 1.00 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL29398210 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL8906393 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL7207049 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL7472 | 0.98 | ADRA2A (1.00) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| Bisantrene SCHEMBL1649622 | 0.97 | ADRA2A (0.97) | ADRA2AADRA1ACHRM2HTR1AADORA3 | |
| SCHEMBL23323322 | 0.92 | ADRA2A (0.86) | ADRA2AADRA1ACHRM2HTR1AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025445-A1 | METHOD OF CARDIOPROTECTION | RACE ONCOLOGY LTD. (AU) | 2025-01-23 | — | — | US | disclosed |
| US-20240100021-A1 | Combination Therapy Schedules to Treat Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-03-28 | — | — | US | disclosed |
| EP-4281068-A1 | COMBINATION THERAPY SCHEDULES TO TREAT CANCER | Board of Regents, The University of Texas System (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022159497-A1 | COMBINATION THERAPY SCHEDULES TO TREAT CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-28 | — | — | WO | disclosed |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-19 | — | — | US | disclosed |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2021-10-05 | — | — | US | disclosed |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2020-05-28 | — | — | US | disclosed |
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | SG CREDIT PARTNERS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2020-02-04 | — | — | US | disclosed |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-03-14 | — | — | US | disclosed |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2018-09-13 | — | — | US | disclosed |
| US-9993460-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-06-12 | — | — | US | disclosed |
| US-9974774-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (AU) | 2018-05-22 | — | — | US | disclosed |
| US-20160220537-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-08-04 | — | — | US | disclosed |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | RACE ONCOLOGY LTD. (AU) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163939-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | ADRA2A 2367/4885ADRA1A 2020/4885CHRM2 3998/4885 |
| US-20250025445-A1 | METHOD OF CARDIOPROTECTION | TNNI3, TNNT2, FABP3 | ADRA2A 202/4885ADRA1A 161/4885CHRM2 1190/4885 |
| US-11135201-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, HCCS, MCL1 | ADRA2A 2752/4885ADRA1A 2132/4885CHRM2 4009/4885 |
| US-11147800-B2 | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, MCL1 | ADRA2A 2367/4885ADRA1A 2020/4885CHRM2 3998/4885 |
| US-20200163940-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, HCCS, MCL1 | ADRA2A 2752/4885ADRA1A 2132/4885CHRM2 4009/4885 |
| US-20190076404-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | ADRA2A 1756/4885ADRA1A 1197/4885CHRM2 3122/4885 |
| US-20180256549-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | ADRA2A 2367/4885ADRA1A 2020/4885CHRM2 3998/4885 |
| US-20160220537-A1 | COMPOSITIONS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, CYP11B2 | ADRA2A 1756/4885ADRA1A 1197/4885CHRM2 3122/4885 |
| US-20240100021-A1 | Combination Therapy Schedules to Treat Cancer | TYMP, DPYD, TP53 | ADRA2A 3538/4885ADRA1A 4227/4885CHRM2 4024/4885 |
| US-20160166546-A1 | COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE AND ANALOGS AND DERIVATIVES THEREOF | CYP3A43, CYP11B1, MCL1 | ADRA2A 2367/4885ADRA1A 2020/4885CHRM2 3998/4885 |
| US-10548876-B2 | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | CYP3A43, CYP11B1, CYP11B2 | ADRA2A 1756/4885ADRA1A 1197/4885CHRM2 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.